The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Somatuline Autogel Preference and Health Economy Study
Official Title: A Phase IV, International, Open-label, Randomised, Cross-over Study to Assess Patient Preference and Health Economy in Patients With Neuroendocrine Tumours, Treated With Lanreotide Autogel Given as Self Administration.
Study ID: NCT00681187
Brief Summary: The primary aim of this study is to assess which method of lanreotide Autogel administration patients with neuroendocrine tumours prefer - self/partner administrations or healthcare provided administrations. The study will also assess if self/partner administration can be performed without loss of efficacy and with a preserved safety profile. The impact of self/partner administration on resource utilisation and costs will be studied. In addition, we will also assess the healthcare provider's experience of the two administration practices.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Aarhus University Hospital / Medisinsk afd. V, Aarhus, , Denmark
Odense Univeristy Hospital / S-AMB, Odense, , Denmark
Haukeland University Hospital / Kreftafd, Bergen, , Norway
University Hospital North-Norway / GastroLab, Tromsø, , Norway
S:t Olavs Hospital / Medisinsk Afd, Trondheim, , Norway
Sahlgrenska University Hospital / Kirurgkliniken, Gothenburg, , Sweden
Linköping University Hospital / Onkologen, Linköping, , Sweden
Karolinska University Hospital, Huddinge / GastroCentrum Medicin, Stockholm, , Sweden
Karolinska University Hospital, Solna / Kirurgmottagningen, Stockholm, , Sweden
Akademiska Hospital/ Kliniken f onkologisk endokrinologi, Uppsala, , Sweden
Name: Ipsen Medical Director
Affiliation: Ipsen
Role: STUDY_DIRECTOR